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ABSTRACT 
SHERITHA P. LEE:  Chronic Inflammation in Sickle Cell Disease: Potential Role of 
Platelets and the Inflammatory Mediator CD40L 
(Under the direction of Leslie V. Parise, PhD) 
 
 
 
Chronic inflammation is a poorly understood, but problematic, manisfestation of sickle cell disease 
(SCD).  The potent inflammatory mediator CD40L increases leukocyte proliferation, endothelial 
adhesiveness and procoagulant activity once it is exposed and released from encrypted sites following 
platelet activation.  Since elevated leukocyte counts, adhesion and coagulation are associated with 
more clinically severe courses of SCD along with platelets that are more activated than normal, 
platelet CD40L is hypothesized to be an important mediator of inflammation in SCD.  Data shown 
here indicate that CD40L is thirty-fold higher in SCD plasma but significantly reduced in SCD 
platelets.  SCD plasma induces B cell proliferation, endothelial activation and procoagulant tissue 
factor production, all in a manner partially dependent on recognition of CD40L.  When CD40L 
activity was blocked in a mouse model of SCD, lung, liver and kidney pathology was demonstrably 
reduced.  More dramatically, anti-CD40L treatment of SCD mice prevented the architectural 
disruption and drastic enlargement of the spleen that is characteristic of SCD.  These data suggest that 
functional CD40L is available and likely mediates inflammation in SCD.  Furthermore, in a phase I 
clinical trial, the αIIbβ3 antagonist eptifibatide reduced plasma CD40L, favorably altered the 
inflammatory cytokine profile of SCD plasma and was well-tolerated by SCD patients.  This study 
provides the first evidence that inflammation and organ pathology in SCD are mediated by platelet-
derived CD40L.  Since plasma CD40L can be safely reduced by anti-platelet medication, we identify 
both CD40L and platelets as potential therapeutic targets to treat SCD.  
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CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
  
Historical Overview 
Sickle cell disease (SCD) can be traced back as far as 1670 in 9 successive generations of at 
least one Ghanaian family.1  Long-standing beliefs and practices of the Yoruba and Ibo of 
Nigeria suggest that Africans may have had an awareness of SCD that predates oral and 
written histories.2,3  The transport of millions of Africans via the Atlantic slave trade led to 
the dispersal of the sickle gene and SCD throughout the Americas.4  The disease first came 
to the attention of Western medicine in 1910 when the blood cells of an anemic West Indian 
student were described as abnormally sickle-shaped.5 
 
Later studies showed that sickling is reversible6 and occurs in response to a decrease in 
oxygen,7 suggesting the involvement of hemoglobin (Hb).  The relationship became clearer 
when Hb from SCD patients, like the red cells, was observed to aggregate upon 
deoxygenation.8  The differential electrophoretic mobility of normal and sickle Hb shown in 
19499 led to the theory that the ordered structure of the abnormal Hb causes sickling,9 
making SCD the first molecular disease to be identified.  The substitution of valine for 
glutamic acid in the sixth amino acid position of the Hb β chain was reported in 1956.10 
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Since that time, SCD has been the model disease for many fields of biomedical as well as 
social science.  It was the first disease to be attributed to a mutation of a specific protein10, 
the first disease to be shown to exhibit Mendelian properties of inheritance11, and the 
landmark disease by which many racial and sociopolitical precedents have been set.  The 
study of SCD has attracted many of the best and brightest scientists of the twentieth century.  
However, despite the knowledge that has amassed, not enough has been translated into 
effective treatment for the many people around the world who still suffer with this disease.  
Widespread use of hydroxyurea has resulted in fewer and shorter pain episodes as well as 
decreased incidences of acute chest syndrome12 for those who can tolerate the drug, but 
toxicity puts limitations on its use. Stem cell transplantation is also promising; however, 
high risk and limited access prevent this treatment from being the panacea many thought it 
would be.  We are still waiting for the gene therapy that will cure the disease and/or the 
miracle drug that will make pain episodes a thing of the past.  Until then, the approaching 
one-hundredth year anniversary of SCD research marks a time filled with both 
disappointment and promise.  Sickle cell patients are living longer, more productive lives; 
but every new finding, every insight gained, is still needed to put an end to the suffering.   
 
 
Sickle cell disease is a chronic inflammatory condition. 
Sickle cell disease is a multi-factorial syndrome.  Hemoglobin polymerization leads to 
abnormally rigid and adhesive red blood cells (RBC) that obstruct blood vessels, leading to 
tissue damage from poor perfusion.13  Recent reports have begun to describe sickle RBC as 
irritants that provoke inflammation14 as they stimulate and damage surrounding tissues and 
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cells.  Therefore, normal cellular responses to these stimuli become pathogenic and 
chronically inflammatory in the abnormal context created by the mutant Hb S.  In fact, 
polymorphic differences in genes involved in inflammation are increasingly being thought of 
as reasons for the varying clinical courses of SCD patients.15  Inflammation exacerbates 
vascular occlusion in SCD because of mutual feedback loops by which inflammation and 
coagulation are intertwined.16 
 
Multiple manifestations of inflammation exist in SCD. 
The classic definition of inflammation is an elevation in leukocyte counts.  Patients with 
SCD have an abnormally high leukocyte count even in the absence of infection17.  Baseline 
leukocyte counts are believed to be predictive of clinically severe SCD, a risk factor for brain 
infarcts18, acute chest syndrome19, as well as early death20.  Case reports also document that 
leukocyte growth factors can bring about these undesirable outcomes in SCD patients.21  
Furthermore, the activation status of leukocytes is a predictor of clinically severe SCD,22 and  
intravital microscopy of SCD mice demonstrate that leukocytes may actually initiate vascular 
occlusion.23  Therefore, the high leukocyte count is inextricably linked to SCD pathogenesis, 
both as an indicator of inflammation, but also as a causative factor.  
In addition to elevated WBC counts, patients with SCD have elevated levels of the 
inflammatory markers C-reactive protein24,25, tumor necrosis factor-α and interleukin-126-28.  
Vascular cells reportedly expressing an activated phenotype in SCD include endothelial 
cells29, neutrophils30,31, monocytes24,32 and platelets.33,34  
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Platelets likely play a role in SCD inflammation. 
It is our hypothesis that platelets lie at the heart of the chronic inflammation in SCD. 
Virchow proposed in 1856 that endothelial injury, hemostasis, and a hypercoaguable state are 
the basis for thrombotic activity 35. Our current understanding of SCD includes evidence that 
all three components of Virchow’s triad exist in these patients with thrombosis likely at the 
center of the inflammatory activity.  Indeed, platelets are chronically hyperactive in SCD,34,36 
and platelets increase sickle RBC adhesion to the endothelium.37  However, the extent to 
which platelet activity contributes to SCD pathology or which of the many platelet functions 
contribute to SCD is still undefined. 
 
Previous reports have suggested that platelets have the potential to contribute to SCD via a 
minimum of 5 ways: 
• Platelet α granules expose P-selectin and release adhesion factors. 
• Platelet dense granules release proaggregatory and inflammatory factors. 
• Platelets promote procoagulant activity through initiation of the coagulation cascade. 
• Platelets aggregate.  
• Platelets expose and release CD40L. 
Understanding platelet activation in the context of SCD may be essential for understanding 
and alleviating symptoms of the disease. 
 
Platelet α granules expose P-selectin and release adhesion factors 
The exposure of P-selectin to the platelet surface38 and an increase in soluble P-selectin39  
correlate positively with pain episodes in SCD. Platelet P-selectin may serve only as a 
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marker of platelet activation and not have a direct role in SCD pathology;23 however, P-
selectin is known to adhere to sickle RBC40 and may increase the aggregation of platelets to 
leukocytes.41  Furthermore, platelet P-selectin may increase endothelial activation,42 which 
likely contributes to vaso-occlusion due to increased sickle RBC adhesion.  Platelet α 
granules also release the glycoproteins fibrinogen, fibronectin, vitronectin, von Willebrand 
factor, and thrombospondin.43  The higher plasma fibrinogen concentration may then 
increase RBC adhesivity to the endothelium,44 while the vitronectin receptor is reportedly 
upregulated in SCD and promotes neutrophil adhesion.39  Fibronectin, von Willebrand factor, 
and thrombospondin are adhesive to sickle RBC under flow conditions.45,46  In addition to 
supporting adhesion, thrombospondin increases sickle RBC adhesiveness by transmitting 
signals through the RBC receptor CD47, or integrin-associated protein to activate α4β1.47  
Thrombospondin and von Willebrand factor also contribute to adhesion by acting as bridges 
between sickle RBC and the endothelium48-50 and von Willebrand factor may link platelets to 
the endothelium.51  Therefore, platelet α granules may contribute to SCD by releasing factors 
that upregulate adhesion. 
 
Platelet dense granules release pro-aggregatory and proinflammatory factors 
Upon activation, platelet dense granules can contribute to increased platelet aggregation by 
releasing adenine nucleotides, inflammatory factors, and bivalent cations.43  Adenosine 
diphosphate (ADP) stimulation of purinergic receptors is a major mechanism of platelet 
activation.52  Therefore, the release of ADP from platelet dense granules plays a critical role 
in hemostasis by recruiting other platelets and perpetuating platelet activation.52  Since the 
platelets of SCD patients in crisis are depleted of ADP stores,53 ADP may increase SCD 
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pathology via this mechanism.  Dense granules may also contribute to SCD pathology 
through the release of inflammatory factors.  Serotonin (5-HT) is a major component of 
dense granules,43 and can exacerbate SCD through its ability to cause vasoconstriction,54 
augment the activity of other vasoconstrictors,55 and induce platelet aggregation.56  Serotonin 
may also activate and recruit neutrophils57 that may contribute to vaso-occlusion.  
Furthermore, 5-HT may promote coagulation58 in a tissue factor-dependent manner.59  Dense 
granules also contain and release the inflammatory mediator histamine, which recruits 
leukocytes57,60  These dense granule components could participate in SCD pathology by 
increasing coagulation, slowing blood flow and promoting vaso-occlusion. 
 
Platelets promote procoagulant activity through initiation of the coagulation cascade 
Upon agonist stimulation, platelets release fibrinogen,43 which then acts as a substrate for 
thrombin to cause clot formation.61  SCD patients have higher levels of fibrinogen62, 
prothrombin and thrombin-anti thrombin complexes63, indicating increased coagulant 
activity.  In addition, many of the clotting factors important to the coagulation cascade are 
also released from platelets upon agonist stimulation.43  Factors V, VII, XI and XIII are all 
housed in and released from platelet α granules.  Therefore, an increase in platelet activation 
logically increases coagulation and subsequently vascular occlusion in SCD.  Furthermore, 
plasminogen, also released from platelets,43 is thought to increase matrix metalloproteinase 
activity once it is converted to plasmin.64  In SCD, this may be the mechanism by which 
endothelial cells65 are released from the blood vessel wall to circulate and adhesive 
subendothelial extracellular matrix proteins45 become exposed to flowing RBC. 
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Platelets aggregate 
The extent to which platelet aggregation contributes to SCD pathology is unknown; however, 
both increased platelet aggregation34 and platelet exhaustion from increased66 in vivo activity 
are reported in SCD.  A transient drop in platelet count that accompanies the onset of painful 
crises67 suggests that platelet aggregation occurs during the initial phase of a crisis and may 
play an essential role in the process.  An increase in circulating platelet aggregates in SCD 
crisis patients68 provides further evidence that platelet aggregation may play a role in the 
clinical status of SCD patients.  Therefore, inhibition of platelet aggregation may be 
beneficial to SCD patients. 
 
Platelets expose and release CD40L 
The potential role of platelets in SCD has been suggested for some time; however, the role of 
platelet CD40L has only recently been considered.69,70  CD40L is a type II transmembrane 
protein and a member of the tumor necrosis factor superfamily.71  Inducibly expressed on 
leukocyte subsets, smooth muscle, and epithelial cells, CD40L mediates a broad variety of 
immune and inflammatory responses72 both in its membrane-bound form and as a soluble 
fragment.73,74  CD40L is upregulated in diverse clinical settings including rheumatoid 
arthritis, neurological disorders, graft-vs-host disease, lung inflammation and chronic 
lymphocytic leukemia.71,75,76  The findings that CD40L plays a prominent role in 
atherosclerosis77 and that platelets express and release it upon activation78 suggest the 
potential involvement of platelet CD40L in other inflammatory vascular diseases, including 
SCD.  Furthermore, since the proinflammatory cytokines TNFα, IL-1, IL-4 and protein 
kinase C that induce CD40L expression72 are upregulated in SCD,79 increased CD40L 
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expression and activity are hypothesized to be important for chronic inflammation in SCD.  
Some potential mechanisms of CD40L involvement in SCD pathology are outlined. 
 
CD40L may induce leukocyte proliferation 
B lymphocyte differentiation and proliferation are the original functions attributed to 
CD40L early after discovery of the protein.75,80  Subsequently, CD40L was shown to 
also regulate leukocyte counts by rescuing monocytes and dendritic cells from 
apoptosis.72  Either function of CD40L might explain the elevated leukocyte counts 
observed in SCD patients.13 
 
CD40L may increase cell adhesion by upregulating adhesion molecules and 
extracellular matrix exposure  Lymphocytes increase ICAM and αLβ2 expression in 
response to CD40L,81 while endothelial cells increase P-selectin, E-selectin, VCAM 
and ICAM upon recognition of CD40L.71,82  These increases in adhesion molecule 
expression may exacerbate SCD by increasing adhesive interactions between blood 
cells and the endothelia that might slow blood flow and increase the propensity of 
vascular occlusion.  Studies in SCD mice indicate that endothelial P-selectin exposure 
may be critical to initiating vaso-occlusion.23  Furthermore, CD40L-mediated 
alterations in matrix metalloproteinases83 potentially explains the prevalence of 
circulating endothelial cells in SCD.29  Upon exposure, extracellular matrix proteins 
may then support sickle RBC adhesion.45 
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CD40L may promote coagulation via an increase in tissue factor 
CD40L regulates endothelial cell procoagulant activity during inflammatory 
responses by inducing expression of the coagulation initiator tissue factor and by 
downregulating thrombomodulin expression.84  This activity is thought to be critical 
to plaque development in atherosclerosis77 and may complicate SCD by contributing 
to the hypercoaguable state85 of the vascular system of these patients. 
 
CD40L upregulates production of inflammatory cytokines 
Patients with SCD reportedly have increased levels of IL-1, IL-6, IL-8, and TNF.79  
These cytokines are thought to increase vaso-occlusion by increasing adhesive 
interactions in the vasculature of SCD patients.  IL-1 and TNF activate endothelial 
expression of the adhesion molecule VCAM,86,87 while IL-8 is thought to activate the 
VCAM receptor α4β1 on sickle reticulocytes.88  IL-1 and IL-6 induce secretion of 
plasma fibronectin89, which can also activate and bind α4β1.90  Expression of all of 
the aforementioned cytokines can be upregulated by CD40L.71 
 
Integrin αIIbβ3 is essential to platelet activation and CD40L release 
The integrin αIIbβ3 is required for platelet release of the inflammatory mediator CD40L.91  
Upon binding to agonist, αIIbβ3 participates in bi-directional signaling critical for platelet 
aggregation, adhesion, granule secretion, and procoagulant activity.92  The platelets of 
patients lacking αIIbβ3 fail to aggregate in response to agonists,93 demonstrating the 
essential role that this integrin plays in platelet activity.  Furthermore, blockade of αIIbβ3 
inhibits thrombotic vessel occlusion94 and the prothrombin activation that leads to 
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coagulation.95  As the most abundant glycoprotein on the platelet surface,96 αIIbβ3 plays a 
critical role in thrombosis and hemostasis.  The role of αIIbβ3 in CD40L release91 suggests 
that this integrin regulates inflammation as well.  Therefore, antagonism of αIIbβ3 is 
proposed as an effective tool to study the role of platelet activation and aggregation in SCD.    
 
 
Specific Aims of the Dissertation 
CD40L mediates chronic inflammation in multiple disease states.71  This inflammatory 
mediator increases B cell proliferation,75 endothelial adhesion molecule expression,72 and 
procoagulant activity through upregulation of tissue factor.97  A similar inflammatory profile 
is known to exist in SCD13 but by an unknown mechanism.  Platelets contain 95% of the 
circulating CD40L.98  Upon activation, this CD40L is exposed to the platelet surface and 
released as a soluble fragment into the plasma.99  Platelets of sickle cell disease (SCD) 
patients are known to be more activated than the platelets of normal individuals, suggesting 
CD40L might be more available and mediating chronic inflammation in these patients.  
However, the role of platelets and the inflammatory protein CD40L in SCD pathology is 
unknown.  Therefore, platelets may participate in the chronic inflammation of SCD via 
CD40L.  This hypothesis was tested with the following specific aims.   
 
Aim 1. Determine if CD40L potentially contributes to SCD pathology.  
In disease states where CD40L is thought to contribute to the disease process, CD40L 
is reportedly elevated.  We measured CD40L levels in SCD patients and compared 
our results to findings from normal individuals. We then assessed the correlation 
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between elevated CD40L and the clinical state of SCD patients by comparing CD40L 
levels in steady state vs. crisis patients.  We also determined if the endogenous 
CD40L in SCD patient plasma is biologically active using established CD40L 
functional assays.  Finally, we provided evidence that platelets are the source of 
CD40L in SCD plasma.   
 
Aim 2. Determine if CD40L contributes to SCD pathology in vivo. 
The relative contribution of CD40L to SCD pathology in vivo was explored using a 
mouse model of SCD.  We generated SCD mice by transplanting hematopoietic stem 
cells from the bone marrow of a SCD transgenic mouse into lethally irradiated 
recipients.  Mice were then treated with an anti-CD40L antibody shown to block 
association of the inflammatory mediator with its receptor.  Accumulated organ 
damage was compared in mice receiving the anti-CD40L compared with non-specific 
controls.  The relative importance of endothelial recognition of CD40L was also 
assessed by imposing the SCD phenotype unto mice lacking expression of potential 
CD40L receptors, CD40 and β3 integrin.  
 
Aim 3. Determine the role of platelet activation in SCD.  
The role of platelets was explored in the context of SCD by blocking the major 
platelet integrin αIIbβ3 in human patients.  Blockage of this integrin not only 
inhibited platelet aggregation, but also inhibited CD40L release from platelets.  
CD40L levels and the prevalence of platelet activation markers were assessed in 
patients receiving the αIIbβ3-antagonist eptifibatide.  The relative changes in the 
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inflammatory profile of plasma from these patients was also compared before and 
after the eptifibatide infusion.  
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CHAPTER II. 
Specific Aim 1.  Determine if CD40L potentially contributes to SCD pathology. 
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Ligand Is Elevated in Sickle Cell Anemia: Potential Role for Platelet-mediated Inflammation. 
ATVB 2006;26(7):1626-31. ©Lippincott Williams & Wilkins. Baltimore, 2006. 
 
Rationale 
Chronic inflammation is one of the many manifestations of sickle cell disease (SCD).1  
Patients with SCD are prone to recurrent infections and increased leukocyte counts2 even 
during the steady state.  Painful crises, the major complication suffered by SCD patients, are 
the result of vascular occlusion3 due to interactions of activated blood and endothelial 
cells.1,4 
 
The polymerization of mutated SCD hemoglobin leads to red blood cell (RBC) sickling5 and 
membrane anomalies6,7 that make sickle RBC abnormally adhesive.3,8-10  Painful vaso-
occlusive crises may partly result from these adhesive RBC interacting with adhesion 
receptors on inflamed endothelia.11  Indeed, RBC adhesiveness12 and higher WBC counts13 
correlate with clinically severe SCD.  However, inflammatory mediators leading to these 
abnormalities in SCD are not well understood.  
 
CD40L is a TNF family member that potentially mediates inflammation in SCD.  Classically 
known as the T cell membrane protein that induces B cell differentiation and 
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immunoglobulin class-switching,14  CD40L is now known to be expressed on a variety of 
cell types, including platelets.14,15  Upon activation, CD40L is exposed to the platelet 
surface,15 then cleaved to generate a soluble product16 that retains the ability to  activate its 
widely expressed receptor CD40.14  The CD40:CD40L interaction is thought to contribute to 
inflammation in systemic lupus erythematous (SLE),17 atherosclerosis,18 and chronic 
lymphocytic leukemia.19  The soluble form of CD40L also mediates prothrombotic activity 
by binding to the platelet integrin glycoprotein (GP) IIb-IIIa20 and  promotes procoagulant 
activity through upregulation of tissue factor (TF).21-23  Chronic inflammation, increased 
thrombotic activity, and hypercoagulation are known aspects of SCD.24,25  However, the 
status of sCD40L in SCD is unknown.  We hypothesized that platelet-derived sCD40L may 
be elevated in SCD as it is in other disease states and that recognition of CD40L by its 
receptor, CD40 may contribute to SCD pathology.  However, the amount of soluble CD40L 
circulating in SCD patients and the role it plays in the disease has not been examined.  
Therefore, the goal of this aim is to determine if CD40L potentially contributes to SCD 
pathology.   
 
 
Materials and Methods 
Human Subjects 
This study was approved by the UNC Committee on the Protection of the Rights of Human 
Subjects.  Informed consent was obtained in accordance with the Declaration of Helsinki.  
Study subjects were hemoglobin S homozygotes aged 20 to 63 years.  Patients in crisis were 
defined as those hospitalized for a painful vaso-occlusive event, without respect to crisis 
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phase.  Steady state patients had not experienced a pain episode requiring acute intervention 
within the previous two weeks.  SCD patients who had received blood transfusions or 
experienced symptoms not attributed to SCD within the previous two weeks were excluded, 
as were patients diagnosed with other inflammatory or malignant conditions.  Controls were 
normal, healthy adults from 19 to 49 years old, and included both African-American and 
Caucasian subjects. 
 
Preparation of human plasma and platelets 
Peripheral blood samples were collected by venipuncture into either 0.13 M sodium citrate or 
ACD.  Blood samples were processed within 90 minutes of blood draw.  To obtain platelet- 
and microparticle-free plasma (PFP), samples were centrifuged at 200g for 15 minutes to 
remove red and white cells, then once at 750g for 20 minutes to remove platelets, and once at 
16,000g for 20 minutes to remove microparticles.  Platelet quiescence was maintained by 
resting samples for 15-30 minutes at 37°C before every centrifugation.  Prostacyclin 
(5 ng/mL) was added to platelet-rich plasma prior to the second centrifugation and to 
platelet-poor plasma prior to the third centrifugation. 
 
For samples used in ELISAs, PFP was defibrinated (1U/mL thrombin) as recommended by 
sCD40L ELISA manufacturer instructions.  Plasma defibrination did not further elevate 
CD40L levels.  Samples were stored at -80°C as per manufacturer’s instructions until use in 
sCD40L (Alexis Biochemicals, San Diego, CA) and TF (American Diagnostica, Greenwich, 
CT) ELISAs. 
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Platelet CD40L levels 
To measure platelet CD40L levels, platelet pellets were collected following a 20-minute 
centrifugation at 750g.  Platelets were carefully resuspended in a modified Tyrode’s buffer of 
5 mM HEPES, 135 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1 mM 
MgCl2, 1 mg/ml dextrose, 1 mg/ml BSA, 50 U/ml heparin, and 10 µg/ml apyrase, pH 6.5.  
Platelets were standardized to 3x108 platelets/ml following counting in a Beckman Coulter 
counter, then lysed in 10 mM CHAPS, 0.5% deoxycholate, 137 mM NaCl, 20 mM HEPES, 
and a broad-spectrum protease inhibitor cocktail (CalBiochem, La Jolla, CA).  
Concentrations of solubilized CD40L in the resulting lysates were then determined by ELISA 
as above.  
 
B cell proliferation 
Ramos B cells were maintained in RPMI-1640 + 10% fetal bovine serum (FBS) at 37°C in 
5% CO2.  For proliferation experiments, B cells were incubated for 72 hours in RPMI-1640 + 
10% human plasma prepared as indicated above, without defibrination.  sCD40L was 
precipitated from samples by incubating plasma with glutathione sepharose beads 
(Amersham Biosciences) and either anti-CD40L or non-specific control rabbit IgG overnight 
at 4ºC.  3H-thymidine (1U/mL of culture media) was added during the last 18 hours of 
culture.  
 
Monocyte tissue factor production 
THP-1 monocytic cells were grown in RPMI-1640 + HEPES + 10% FBS at 37°C in 5% CO2.  
For TF induction experiments, THP-1 cells were incubated in 10% human plasma that was 
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prepared as described above, but without defibrination.  Following addition of either anti-
CD40 (ATCC#HB-11339) or control antibody, THP-1 cells were incubated for 24 hours, 
then washed 3X in PBS before being lysed with 1% NP-40 in a Tris-based lysis buffer 
containing 150 mM NaCl and 2 mM EDTA, pH 7.5.  
 
Endothelial cell isolation and culture 
Collagenase (1 mg/ml) was used to harvest human umbilical vein endothelial cells (HUVEC) 
from the cannulated vein of human umbilical cords as described.26  HUVEC were then 
cultured in M199 media with 20% FBS, heparin, non-essential amino acids, endothelial cell 
growth factor, penicillin and streptomycin. HUVEC were used from passages 2-4. 
 
Cell surface ELISA 
HUVEC were grown to over-confluence to induce quiescence in 12-well tissue culture 
dishes, then treated with 10% human plasma for 24 hours.  Plasma was prepared as above, 
but was not defibrinated.  For inhibition experiments, rabbit anti-human CD40 polyclonal 
antibody (Research Diagnostics, Flanders, NJ) or rabbit IgG were added 30 minutes prior to 
treatment with human plasma.  Cells were washed 3X with PBS, fixed with 1% 
paraformaldehyde, then blocked with 10% non-fat dry milk.  A monoclonal antibody against 
ICAM-1 (Serotec, Inc., Raleigh, NC) at 1 µg/ml was incubated overnight at 4°C, followed by 
an anti-mouse IgG:horseradish-peroxidase conjugate, with 3X PBS + 0.1% Tween-20 washes 
between each step.  Reactions were developed in tetramethylbenzidine (Sigma) and stopped 
with 2N H2SO4.  Absorbance was read at 450 nm. 
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Statistical Analyses 
All data are presented as mean ± standard deviation.  Levels of soluble CD40L in human 
plasma were compared using nonparametric Wilcoxon sum rank tests as computed by SAS 
Proc Npar1way where average scores were used as ties.  The student’s t test was used to 
determine significance for all other data, at a power of 0.1. 
 
 
Results 
CD40L is elevated in the plasma of SCD patients 
To determine if CD40L is elevated in SCD, sCD40L levels were measured by ELISA in 
platelet- and microparticle-free plasma (PFP).  PFP was prepared by centrifugation of 
quiescent platelet-rich plasma under conditions determined to prevent platelet activation or 
contribution of microparticles, as described in Methods.  The average concentration of 
sCD40L in SCD plasma (1.31 ± 1.74 ng/ml) was 30-fold higher than sCD40L found in 
normal plasma (0.04 ± 0.05 ng/ml, Figure 1).  This value is several fold higher than in 
chronic lymphocytic leukemia19 and acute coronary syndromes18 where sCD40L is thought 
to contribute to the disease process.  CD40 ligand levels in SCD plasma varied greatly among 
patients, ranging from normal values (i.e. 0.03 ng/ml) to values 150-fold higher (i.e. 
6.0 ng/ml).  sCD40L levels of SCD patients in crisis were further elevated by 79% when 
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compared to steady state (Figure 1), suggesting that higher levels of sCD40L correlate with 
the clinical status of SCD patients.  
 
Platelet CD40L is decreased in SCD and further depleted during crises 
Since more than 95% of circulating CD40L is contained within platelets27 and released 
following platelet activation,16 we examined the possibility that the chronically activated 
platelets believed to exist in SCD patients28-30 might be the source of sCD40L in SCD 
plasma.  Using the same ELISA assay, CD40L levels were measured from resting platelet 
lysates of SCD patients and normal individuals.  We found that platelets from SCD patients 
contained less than half of the CD40L found in platelets from normal individuals (5.69 ± 
4.81 ng/3x108 platelets versus 13.30 ± 6.77 ng/3x108 platelets, Figure 2A).  This two-fold 
difference is more than enough to account for the elevated CD40L measured in the plasma of 
SCD patients.31  Furthermore, the resting platelets of SCD patients in crises contained less 
than half of the CD40L than platelets of patients in the steady state (2.97 ± 2.81 ng/3x108 
platelets versus 7.08 ± 5.26 ng/3x108 platelets, Figure 2B).  These results provide evidence 
that platelets are a major source of elevated CD40L in SCD and suggest an association 
between decreased platelet CD40L, increased plasma CD40L and painful crises in SCD 
patients. 
 
Tissue factor levels are elevated in SCD and correlate with elevated CD40L 
Since CD40L mediates expression of the coagulation initiator TF,23 we speculated that 
elevated CD40L may contribute to hypercoaguability in SCD plasma by upregulating TF 
production.  Therefore, we compared the levels of TF in SCD and normal plasma (713.11 
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pg/ml ± 420.84 pg/ml vs. 6.34 pg/ml ± 12.34 pg/ml, Figure 3A).  SCD plasma contained over 
100-fold greater TF than the plasma from normal controls.  Furthermore, elevations in TF 
correlated with elevations in sCD40L in matched SCD plasma samples at a level of R2 = 
0.600 (Figure 3B). 
 
CD40:CD40L interaction augments SCD plasma-induced TF production by monocytes 
Monocytes are known to respond to CD40L stimulation with increased TF production, thus 
promoting procoagulant activity.32  We therefore asked whether SCD plasma increases TF 
production by monocytes, and if so, whether this increase is dependent upon the 
CD40:CD40L interaction.  Lysates of monocytic THP-1 cells were assayed for TF following 
incubation with plasma from either SCD patients or normal volunteers.  SCD plasma induced 
a significant increase in TF production relative to plasma from normal individuals or media 
alone.  Optical density readings indicating relative TF expression were two-fold greater in 
lysates from SCD plasma-treated THP-1 cells than from THP-1 cells treated with normal 
plasma (Figure 4A).  The CD40:CD40L interaction was not solely responsible for the 
elevation in TF production, but appeared to promote coagulation in some cases as pre-
incubation of the THP-1 cells with a function blocking anti-CD40 antibody, prevented 
increased TF expression in 5 of 8 individual cases (Figure 4B). 
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SCD plasma-induced expression of VCAM-1 and ICAM-1 occurs via CD40:CD40L 
interaction 
Red blood cells from SCD patients are known to induce endothelial cell expression of 
adhesion molecules.33  We found that SCD plasma can also induce surface expression of 
endothelial VCAM-1 and ICAM-1.  Relative to normal plasma, optical density readings were 
two-fold greater corresponding to surface expression of endothelial VCAM-1 and three-fold 
greater corresponding to surface expression of endothelial ICAM-1 as a result of SCD 
plasma treatment (Figure 5A).  Similar to the results obtained with TF production, CD40 
blockade significantly reduced SCD plasma-induced ICAM-1 expression by HUVEC (Figure 
5B), suggesting that the CD40:CD40L interaction can contribute to the adhesive state of the 
endothelium by inducing ICAM-1 expression on these cells.  The reduction in VCAM-1 
expression was lowered by CD40 blockade, but was not statistically significant (Figure 5B). 
 
CD40L in SCD plasma induces B cell proliferation 
A B cell proliferation assay was used to further confirm the biological activity of soluble 
CD40L in SCD plasma.  B cell proliferation was measured by 3H-thymidine incorporation 
following the culture of Ramos B cells in either media alone, plasma from SCD patients or 
plasma from normal volunteers.  We found that B cell incorporation of 3H-thymidine was 31-
fold greater in the presence of SCD plasma versus normal plasma (2.49x10-3 cpm ± 
1.12x10-3 cpm vs. 0.079x10-3 cpm ± 0.028x10-3 cpm, Figure 6A).  Since ligation of CD40 
with anti-CD40 antibodies was found to activate Ramos B cells, the role of the CD40:CD40L 
interaction was investigated by immunoprecipitation of sCD40L from SCD plasma.  Ramos 
B cells treated with sCD40L-cleared plasma exhibited significantly less proliferation than 
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control plasma, with an ~75% reduction in 3H-thymidine uptake.  Proliferation was not 
reduced by control IgG (Figure 6B), indicating that the increased proliferation of B cells by 
SCD plasma is CD40L-dependent and that the sCD40L circulating in SCD patients is 
biologically active. 
 
Discussion 
This study provides new insights into potential mechanisms contributing to inflammatory 
processes in SCD.  CD40L has emerged as a potent mediator of inflammation, with  elevated 
sCD40L levels being observed in a variety of diseases involving vascular inflammation.17-19  
We now find that sCD40L is elevated in SCD as well.  Indeed, our findings indicate an 
average 30-fold elevation of sCD40L in SCD versus normal plasma, with corresponding 
decreases in the amount of CD40L stored in the platelets of SCD patients.  The elevated 
sCD40L in SCD plasma positively correlates with increased TF and participates in the 
induction of TF and ICAM-1 expression via its interaction with CD40.  Biological activity of 
sCD40L in SCD plasma is further confirmed by its induction of B cell proliferation.  
Together, these data identify sCD40L as potentially important for both inflammation and 
coagulation in SCD, and suggest a previously unrealized participation of platelets in SCD 
pathogenesis. 
 
The magnitude of sCD40L elevation in SCD (~30-fold) can be compared to the increased 
levels of sCD40L found in other chronic inflammatory conditions such as SLE (>20-fold),17 
chronic lymphocytic leukemia (2.7-fold)19 and unstable angina (3-fold).18  In all of these 
latter conditions, CD40L is thought to contribute to the disease state.  The 30-fold elevation 
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of sCD40L reported here places CD40L among the inflammatory cytokines potentially 
sharing a causative role in vascular occlusion in SCD.  
 
In addition to platelets, WBC in SCD patients are also depleted of CD40L (data not shown), 
suggesting that both may contribute to the elevated sCD40L in SCD plasma.  However, since 
platelets contain more than 95% of the circulating CD40L,27 and these stores are reduced by 
approximately 57% in SCD (Figure 2), platelets are likely to be the major source of sCD40L 
in SCD plasma.  Indeed, SCD patients average 5.7 ng of CD40L per 3x108 platelets 
compared to 13.3 ng of CD40L found in normal platelets (Figure 2).  Assuming a platelet 
count of 3x108 platelets/ml of plasma, 7.6 ng of CD40L relocated from platelets to the 
plasma would correspond to nearly a 200-fold increase over normal circulating levels of 
0.04 ng CD40L/ml, suggesting that the amount depleted from SCD platelets could more than 
account for the 30-fold elevation found in SCD plasma (Figure 1).  Given that elevated 
sCD40L levels return to baseline within two hours of cardiopulmonary bypass,31 and that the 
amount of sCD40L at sites of thrombosis would presumably be more concentrated, the 
potential exists for soluble CD40L to reach far greater levels than reported here.  The further 
depletion of platelet CD40L during crises suggests a correlation to worsened clinical status of 
SCD patients and leads us to propose that platelets contribute to the chronic inflammation in 
SCD by releasing CD40L into the plasma. 
 
Increased in vivo platelet activation in SCD results in increased CD40L exposure to the 
platelet surface34  Once exposed, the cleavage of CD40L from platelets results in the release 
of sCD40L16 to the plasma and a loss of platelet CD40L.  Therefore, SCD platelets have 
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more surface-exposed CD40L,34 but less total CD40L stored, as measured here in platelet 
lysates (Figure 2).   
 
CD40L may link chronic inflammation and hypercoagulation in SCD.  We confirm here that 
TF, a major initiator of the coagulation cascade, is abnormally elevated in SCD plasma 
(Figure 3A).24  Furthermore, elevated TF in SCD plasma correlates to increased CD40L 
(Figure 3B).  Since monocyte TF production can be induced by SCD plasma (Figure 4) and 
reduced by CD40 blockage, our results suggest that the CD40:CD40L contributes to 
hypercoagulation in SCD,  particularly when taken in context with other studies showing that 
CD40L upregulates TF production.23,35,36  Platelets may therefore contribute to the 
hypercoagulation in SCD via CD40L exposure and release.  
 
Notably, our study indicates that plasma from SCD patients is itself inflammatory.  Plasma 
from SCD patients was sufficient to increase endothelial ICAM-1 expression 3-fold (Figure 
5A), and Ramos B cell proliferation 31-fold (Figure 6A).  Therefore, therapeutic approaches 
targeted to inflammatory plasma components may also be beneficial to SCD patients.   
 
Recent evidence that CD40L provides a novel mechanism of platelet activation37 suggests a 
potential positive feedback loop whereby CD40L participation in SCD may be perpetuated.  
CD40 ligand is thought to cause α− and dense-granule release, potentially maintaining the 
activation profile already characterized by SCD platelet studies.30,34,39  CD40L-induced P-
selectin exposure38 may lead to further procoagulant activity40 and strongly suggests that 
targeting CD40L release or activity may be therapeutically beneficial to SCD patients.  
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Inhibitors of platelet GPIIb-IIIa have shown promising results in acute coronary 
syndromes,41,42 and anti-CD40L treatment reportedly improves the clinical profiles of SLE 
patients.43  SCD patients may be candidates for either of these therapies.  Future studies will 
be necessary to clarify the relative importance of CD40L in context with the other 
inflammatory mediators in SCD plasma, as well as to determine whether the elevated 
sCD40L levels in SCD are as predictive of inflammatory and thrombotic activity in SCD as 
they are in acute coronary syndromes.  
  34
Figure 1 
normal total crisis steady state
0
1
2
3
4
5
6
7
sC
D
40
L 
(n
g/
m
l)
SCD
 
Figure 1. Soluble CD40L is elevated in SCD plasma. Levels of sCD40L were determined 
to be 1.18 ± 1.39 ng/ml in plasma samples from 49 sickle cell (SCD) patients compared to 
0.04 ± 0.07 ng/ml in plasma from 16 normal volunteers by ELISA as extrapolated from a 
standard curve. Total SCD data are significantly different from normal controls (p-value < 
0.0001). Crisis patients have even higher sCD40L levels at 1.89 ± 1.59 ng CD40L/ml of 
plasma from 10 SCD patients in pain crises compared to 1.05 ± 1.33 ng CD40L/ml of plasma 
from 37 steady state SCD patients (p-value = 0.065). 
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Figure 2. Platelets from SCD patients have lower CD40L levels than normal controls 
and are further depleted during crises. (A) Platelet lysates from 21 SCD patients contained 
5.69 ± 4.81 ng CD40L/3 x 108 platelets, or less than half the 13.30 ± 6.77 ng CD40L/3 x 108 
platelets found in 4 normal samples. Data reflect measurement by ELISA and are 
significantly different (p-value = 0.029). (B) Platelet lysates from 13 steady state patients 
contained 7.08 ± 5.26 ng CD40L/3 x 108 platelets, or more than two-fold greater than the 
average 2.97 ± 2.81 ng CD40L/3 x 108 platelets found in platelets from 8 SCD patients in 
crisis. Data reflect measurement by ELISA and are significantly different (p-value = 0.042). 
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Figure 3. Tissue factor is elevated in SCD plasma and correlates with higher CD40L 
levels. (A) The coagulation cascade initiator TF was found to be elevated over 100-fold in 18 
SCD patients compared to normal donors (713.11 pg/ml ± 420.84 pg/ml vs. 6.34 pg/ml ± 
12.34 pg/ml). Data shown represent tissue factor levels as measured by ELISA and are 
significantly different (p-value = 0.0395). (B) Levels of TF in SCD plasma samples were 
plotted against corresponding sCD40L levels measured in the same samples. R2 = 0.600 for 
sCD40L levels < 2.5 ng/ml. 
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Figure 4B 
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Figure 4. SCD plasma-induced monocytic TF is reduced by an anti-CD40 monoclonal 
antibody. (A) Monocytes exposed to plasma from SCD patients produced greater TF than 
monocytes exposed to plasma from normal volunteers. Optical density readings of TF in 
THP-1 lystates are 2X greater following treatment with SCD plasma. (B) In 5 of 8 SCD 
patient samples, an anti-CD40 monoclonal antibody decreased TF production by THP-1 cells 
relative to an isotype-matched control antibody. 
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Figure 5 
Figure 5. Blockage of CD40 on HUVEC inhibits SCD plasma-mediated increases in VCAM-1 
and ICAM-1 expression. (A) Optical density readings corresponding to HUVEC surface expression 
of adhesion molecules were increased two-fold for VCAM-1 and three-fold for ICAM-1 (p-value = 
0.0242) following treatment with SCD plasma from 8 patients compared to plasma from 3 normal 
individuals. (B) ICAM-1 expression could be significantly reduced by pretreatment of HUVEC with 
an anti-CD40 polyclonal antibody (n = 4, p-value = 0.0475). The reduction in VCAM-1 expression 
was not statistically significant.  Non-specific rabbit immunoglobulin had no effect. 
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Figure 6. B cell proliferation increases 35-fold in SCD vs. normal plasma and is inhibited by 
CD40L depletion from plasma. (A) Ramos B cells were cultured in RPMI-1640 + 10% human 
plasma from either SCD patients or normal volunteers. Uptake of 3H-thymidine averaged 0.079 x 10-
3 cpm ± 0.028 x 10-3 cpm in the presence of plasma from 3 normal volunteers and ~31-fold higher 
(2.49 x 10-3 cpm ± 1.12 x 10-3 cpm) in the presence of SCD plasma from 6 patients. (B) Depletion of 
sCD40L by treating SCD plasma with beads plus anti-CD40L polyclonal antibody significantly 
decreased 3H- thymidine uptake by an average of 75% to 0.50 x 10-3 cpm ± 0.61 x 10-3 cpm, versus 
a non-specific rabbit IgG control antibody, which did not inhibit SCD plasma-induced B cell 
proliferation (p-value = 0.002). 
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CHAPTER III. 
Specific Aim 2.  Determine if CD40L contributes to SCD pathology in vivo. 
 
Rationale 
CD40 ligand (CD40L) is a TNF family member1 implicated in the pathogenesis of SCD.2  
Platelet-released CD40L may participate in SCD severity via numerous mechanisms.  
CD40L may be partially responsible for high leukocyte counts3 that are predictive of SCD 
severity4 and early death5 because of the role CD40L plays in inducing leukocyte 
proliferation.6,7  Endothelial adhesion molecule expression may be upregulated by CD40L,8 
potentially leading to increased sickle RBC adhesion to the endothelium.9  Sickle cell 
adhesion may also follow extracellular matrix exposure10 caused by a CD40L-mediated 
increase in MMP production.11 Combined with the ability of CD40L to promote 
coagulation,12 these findings suggest a role for CD40L in SCD vaso-occlusion.   
 
Sickle cell disease is known to be a chronic inflammatory condition13 where multiple 
inflammatory mediators are upregulated.14-16  Elevations in inflammatory cytokines and acute 
phase proteins17 are implicated in disease severity18 and pathology19.  Cytokines may play a 
role in SCD by inducing endothelial adhesiveness20,21, activating platelets and neutrophils15, 
regulating hematopoiesis22, and inhibiting immune functions.23  All of the aforementioned 
factors likely contribute to the exacerbation SCD severity.  Since the manifestations of SCD 
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are likely the combined result of numerous factors, the relative role played by CD40L in this 
inflammatory milieu remains obscure.  Therefore, we sought to determine the relative 
importance of CD40L to SCD pathology in vivo using a mouse model of SCD.24  To 
accomplish this, sCD40L was measured in platelet-free plasma from SCD mice.  Mice 
mimicking SCD were also treated with an anti-CD40L monoclonal antibody shown to 
effectively block CD40L activity in a murine model of atherosclerosis.25  Accumulated organ 
damage in anti-CD40L treated mice was then compared to mice receiving non-specific 
immunoglobulin control.  In addition, the relative importance of CD40L recognition by the 
endothelium will be determined by imposing the SCD phenotype onto mice lacking 
expression of the known possible CD40L receptors, CD40 and β3 integrin.26 
 
 
Materials and Methods 
CD40L ELISA 
Blood was drawn by cardiac puncture from wild-type, sickle and heterozygote mice into 
ACD in the laboratory of Dr. Paul Frenette (Mt. Sinai Medical Center, New York, NY).  
Blood cells were removed by a 200g centrifugation for 15 min, followed by resting the 
resultant platelet-rich plasma at 37°C for 15 min.  Prostaglandin E1 was added to maintain 
platelet quiescence before a second centrifugation of 750g for 20 min to remove platelets.  
Platelets lysed in 1%NP-40 and  platelet-free plasma were stored at -80°C and shipped on dry 
ice where samples were used in a sandwich ELISA. Briefly, CD40L was captured by an anti-
mouse CD40L monoclonal antibody-coated microtiter wells.  CD40L was then sandwiched 
by an anti-CD40L polyclonal antibody, that was in turn detected by a horseradish peroxidase 
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(HRP)-linked anti-rabbit secondary antibody.  A tetramethyl benzidine developing solution 
(Sigma Chemicals) was applied as the HRP substrate and the color reaction was stopped by 
adding 2N H2SO4.  Color was then read at 450nm by a microplate reader and compared to a 
standard curve of known concentrations of recombinant mouse CD40L.  
 
Bone Marrow Transplantation 
Eight-week old wild-type C57BL/6, CD40-/- or β3-/- females were given two doses of total 
body irradiation, 700 Rad and 500 Rad given 4 hours apart, in a cesium-137 irradiator 
(AECL Gammacell 40).  Lethally irradiated mice were then rescued with an injection of 
3x106 bone marrow cells collected from the hind limbs of a genetically bred SCD mouse24 
donor.  In this way, bone marrow transplantation reliably confers the hematopoietic 
phenotype of donor mice unto the genetic background of irradiated recipients.27  In addition 
to standard chow, mice were maintained on acidified neomycin water (1g/L, pH 2.0) for 2-3 
weeks following transplant.  Chimerism was verified by hemoglobin electrophoresis 6-8 
weeks following the transplant.  All mice were housed in a barrier facility maintained by the 
UNC Department of Laboratory and Animal Medicine (DLAM).  Protocols were reviewed 
and approved by the UNC Institutional Animal Care and Use Committee (IACUC). 
 
Anti-CD40L treament 
Bone marrow transplanted (BMT) SCD mice were treated with a monoclonal antibody, clone 
MR1, known to inhibit CD40L activity in vivo.25  Mice were injected intraperitoneally with 
250 µg of low-endotoxin, azide-free anti-CD40L antibody (Taconic) twice per week for 6 
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weeks.  Non-specific, isotype-matched control antibody was also administered to BMT SCD 
mice as control.  Following treatment, blood was drawn by cardiac puncture. 
 
Organ collection and histologic preparations 
Mice were weighed, then placed in a CO2 inhalation chamber until motionless. Mouse organs 
were preserved by cardiac infusion of PBS followed by freshly prepared 4% 
paraformaldehyde, pH 7.2.  The fixation process was continued by incubation of whole mice 
in 4% paraformaldehyde for 7 days.  Mice were then switched to a solution of 70% ethanol 
until organs were collected for histologic preparation.  Lung, liver, kidney and spleen were 
embedded in paraffin, sectioned and mounted on slides.  All organs were stained with 
hematoxylin & eosin (H&E), gomori iron and the fibrin-indicator phosphotungstic acid-
hematoxylin (PTAH) stains.  Paraffin preparation, tissue sectioning and histological staining 
were performed by the DLAM histopathology core facility. 
 
 
Results 
Soluble CD40L may be elevated in SCD mouse plasma and depleted from mouse platelets 
To determine if SCD mice exhibit elevated plasma CD40L levels as seen in humans, an 
ELISA was developed to measure CD40L in mouse platelet-free plasma and platelet lysates.  
Results from samples collected in the laboratory of Paul Frenette (Mt. Sinai, New York, NY) 
demonstrated that  plasma CD40L is 1.3X greater in an SCD mouse (SS) compared to wild-
type (WT), while platelet CD40L is measurably less in the SCD mouse compared to wild-
type (Figure 7).  The heterozygote mouse (SA) expressing one sickle allele also exhibited 
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elevated plasma CD40L, although platelets from this mouse did not contain less CD40L 
(Figure 7). 
 
Splenic abnormalities in BMT SCD mice are reduced by anti-CD40L treatment, but not by 
the absence of potential CD40L receptors from the endothelia 
To determine the relative contribution of CD40L to SCD in vivo, SCD mice were generated 
through bone marrow transplantation, then treated with the anti-CD40L antibody, clone 
MR1, shown to block CD40L activity in a mouse model of atherosclerosis.25  The SCD 
phenotype was also conveyed to CD40-/- and β3-/- mice to determine the importance of 
endothelial recognition of CD40L. Spleens collected from anti-CD40L treated mice did not 
exhibit the dramatic 7-fold enlargement that is characteristic of SCD mice.  Anti-CD40L 
treated mouse spleens, but not IgG control treated, were comparable to normal in percentage 
of mouse body weight (Figure 8A).  Conversely, the absence of CD40 and β3 integrin from 
the endothelia did not result in decreased spleen size (Figure 8A).  Bone marrow 
transplantation alone did not increase spleen size, as WT BMT controls did not exhibit 
splenic enlargement (Figure 8A). 
 
Upon microscopic examination of spleens, the characteristic disruption of splenic 
architecture that is typical in SCD mice was readily observed in BMT mice.  Red-white pulp 
nodular organization was apparent in mice treated with anti-CD40L, but not control IgG 
(Figure 8B).  The lack of endothelial CD40 nor β3 integrin was protective against the 
abnormal splenic architecture induced by the SCD BMT (Figure 8B). 
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Lung pathology in BMT SCD mice is abrogated by both anti-CD40L treatment and the 
absence of CD40 
BMT mice were treated with anti-CD40L antibody, an isotype-matched control IgG, or left 
untreated for 8-10 weeks following the introduction of SS bone marrow.  Histologic 
preparations of perfusion-fixed lung tissue were prepared with H&E, iron and fibrin stains.  
Lungs from anti-CD40L treated mice, compared to lungs from control IgG-treated mice, had 
demonstrably less damage as evidenced by the amount of iron and fibrin deposits (Figure 9).  
The lack of CD40 was also protective against sickle-induced lung pathology in the CD40-/- 
chimeric mice (Figure 9), with lungs virtually free of iron and fibrin deposits.  Conversely, 
the absence of the β3 integrin did not affect accumulated damage to the lungs of the β3-/- 
mice following the sickle BMT procedure (Figure 9). 
 
Anti-CD40L treatment reduces liver and kidney pathology in BMT SCD mice 
Liver and kidney tissue sections isolated from anti-CD40L treated, BMT SCD mice were 
also prepared, staining for iron and fibrin deposits.  Liver sections from the anti-CD40L were 
less positive for both iron and fibrin stains than liver sections from mice treated with a non-
specific, isotype-matched control antibody (Figure 10).  Kidney sections from the anti-
CD40L treated mice contained demonstrably less iron deposits than the IgG control treated 
mice, however fibrin deposits appeared similar for both treatment groups (Figure 10). 
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Non-hematopoietic sources of CD40 and β3 integrin are not required for SCD-induced liver and 
kidney damage.   
Perfusion-fixed liver and kidneys were isolated from chimeric SCD mice expressing the 
sickle phenotype against either a CD40-/- or β3-/- background.  When histologic sections of 
liver and kidney tissue were examined, the absence of CD40 nor β3 integrin from the non-
hematopoietic cells appeared to protect the BMT mice from SCD-induced iron and fibrin 
deposits (Figure 11).   
 
 
Discussion 
CD40L is a potent inflammatory mediator1 known to induce proliferation of some 
leukocytes.6  Upon recognition by its receptor CD40, CD40L also increases endothelial 
expression of cell adhesion molecules1,8 and promotes coagulation through upregulated tissue 
factor production.28,29  The elevated WBC counts5,13, endothelial adhesivity30,31 and 
hypercogulation32 that exacerbate the clinical course of SCD, may be partially explained by 
the activity of CD40L.2  However, multiple inflammatory cytokines are likely involved in the 
clinical manifestations of SCD.15  In this study, we sought to determine the relative 
importance of CD40L to SCD pathology in vivo. 
 
Results presented here infer that sCD40L may be elevated in the plasma of SCD mice 
(Figure 7) just as it is in the plasma of human SCD patients.2  As these data only represent a 
single mouse of each genotype, firm conclusions can not be drawn.  However, the higher 
level of sCD40L found in plasma from a SS homozygote corroborates the fact that the 
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phenotype of the Berkeley SCD mice24 strongly recapitulates human SCD.33  The potential 
elevation of sCD40L in mouse SCD plasma also lends credence to the relative importance of 
this particular characteristic.   
 
When the activity of CD40L was blocked in the SCD mice, we found that organ pathology 
was noticeably diminished.  Namely, the characteristic enlargement of the spleen that occurs 
in SCD was not evident following anti-CD40L treatment (Figure 8A).  In fact, spleens of 
anti-CD40L treated mice were normal in size rather than the gross 7-fold splenic enlargement 
of the IgG control-treated mice (Figure 8A).  Furthermore, well-defined nodules indicative of 
normal red-white pulp splenic architecture was evident in anti-CD40L treated mouse spleens, 
but not in the spleens of mice treated with an isotype-matched control antibody (Figure 8B).  
Larger, more defined areas of white pulp seen in the spleens of the anti-CD40L treated mice 
are seemingly the antithesis of expected results since CD40L is known to mediate 
proliferation of leukocytes found in white pulp.1,6  However, it is important to note that the 
sections shown here are indicative of architectural organization only and do not allow for 
quantitative comparisons of particular cell types to be made.  Regardless, this study becomes 
the first to demonstrate that CD40L participates in SCD-induced splenic enlargement and the 
disruption of splenic architecture. 
 
The data shown here go on to demonstrate that the CD40:CD40L dyad plays a prominent 
role in the development of lung pathology in SCD.  Lung tissue from BMT SCD mice were 
virtually free of iron and fibrin deposits when either CD40L was blocked by anti-CD40L 
treatment or when CD40 was absent from non-hematopoietic cells (Figure 9).  As the 
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absence of non-hematopoietic CD40 did not affect SCD-induced pathology of other organs 
studied (Figure 11), these results highlight differential and organ-specific mechanisms by 
which CD40L participates in the pathology of SCD.  Since anti-CD40L treatment 
demonstrably reduced SCD-induced organ pathology (Figures 8 and 10) in tissues where the 
absence of non-hematopoietic CD40 and endothelial β3 integrin had no effect (Figures 8 and 
11), these results suggest that:  1) CD40L may interact with an unknown receptor; 2) 
Endothelial expression, rather than recognition, of CD40L may be an important mechanism 
of organ damage induced by SCD; or 3) Hematopoietic sources of CD40 and CD40L 
participate in SCD-induced organ damage.  Additional studies aimed at dissecting out the 
specific mechanisms by which CD40L participates in SCD pathology are warranted.  
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Figure 7.  CD40L may be elevated in mouse plasma and depleted in mouse platelets.  CD40L 
was determined to be 0.265 ± 0.001 ng/ml in the plasma of a wild-type C57BL6 mouse (WT) and 
0.317 ± 0.036 ng/3x108 platelets. A heterozygote expressing one human sickle allele (SA) had 
plasma CD40L of 0.315 ± 0.001 ng/ml and 0.322 ± 0.008 ng/3x108 platelets. The homozygote 
SCD mouse (SS) had plasma CD40L of 0.345 ± 0.027 ng/ml and platelet CD40L of 0.299 ± 
0.007 ng/3x108 platelets. Results shown are normalized to wild-type measurements and reflect 3 
iterations of 1 sample from each phenotype. 
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Figure 8 
 
Figure 8. SCD-induced splenic abnormalities are reduced by anti-CD40L treatment, but not by 
the absence of endothelial CD40 and β3 integrin in BMT SCD mice.  (A) The spleens of SS BMT 
mice (n=4) averaged 1.585% of total body weight compared to just 0.485% in AA BMT mice (n=2).  
In CD40-/- mice, spleens were 1.88% and 0.263% in SS (n=3) and AA (n=3) BMT mice, 
respectively.  Spleens from β3-/- mice averaged 2.19% in SS BMT mice (n=2) and 0.305% in AA 
BMT mice (n=2).  Following treatment with an anti-CD40L antibody, spleens of SS BMT mice 
averaged 0.285% of total body weight.  (B) Photographs of 10X magnification of spleen sections 
stained with H&E demonstrate that anti-CD40L treated mouse spleens have the nodular red-white 
pulp architecture that is lost in SCD. IgG control treatment had no effect on spleen size or 
architecture. 
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Figure 9 
 
 
Figure 9.  Lung pathology in BMT SCD mice is abrogated by both anti-CD40L treatment and 
the absence of CD40.  RBC congestion (black arrows) is evident in H&E stained lung sections of SS 
BMT mice, but not in AA BMT controls. Fibrin and iron deposits are noticeably decreased by 
αCD40L treatment as well as the absence of non-hematopoietic CD40. IgG control treatment and the 
lack of non-hematopoietic β3 integrin had no effect on SCD-induced fibrin and iron deposits.  Data 
shown represent photographs of 20x magnification of lung sections. 
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Figure 10 
 
 
Figure 10.  Anti-CD40L treatment decreases liver and kidney pathology in BMT SCD mice.  
Liver and kidney sections from SS BMT mice contain iron and fibrin deposits not found in 
comparable sections from AA BMT control mice. αCD40L treatment reduced iron deposits in 
both liver and kidney sections. Fibrin deposits were visibly reduced in liver, but this reduction 
was not readily apparent in kidneys. Isotype-matched control IgG treatment did not reduce SCD-
induced iron and fibrin deposits to liver and kidney in BMT mice. Data shown represent 
photographs of 20X magnification of liver sections and 10X magnification of kidney sections. 
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Figure 11 
 
 
Figure 11.  Non-hematopoietic sources of CD40 and β3 integrin are not required for SCD-
induced liver and kidney damage.  Liver and kidney sections from SS BMT mice contain iron 
and fibrin deposits not found in comparable sections from AA BMT control mice. These deposits 
of iron and fibrin were evident regardless if the SS phenotype was transplanted onto a WT, 
CD40-/- or β3-/- background.  Data shown represent photographs of 20X magnification of liver 
sections and 10X magnification of kidney sections. 
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CHAPTER IV. 
Specific Aim 3.  Determine the role of platelet activation in SCD. 
 
Rationale 
Sickle cell disease (SCD) is a complex syndrome characterized by a hypercoagulable state of 
multifactorial etiology1.  A quagmire of vaso-occlusive RBC phenomena2 is compounded by 
ischemia-reperfusion injury,3 elevated leukocyte counts, abnormal activation of granulocytes 
and monocytes,4,5 and elevated levels of multiple inflammatory mediators.2  Platelets are also 
thought to contribute to SCD via P-selectin,6-8 endothelial activation9 and aggregate 
formation.10  Platelet-released factors11 increase RBC adhesivity,12,13 coagulation14 and 
vasoconstriction.15,16 
 
Furthermore, platelets expose and release the inflammatory mediator CD40L,17 capable of 
mediating a broad variety of immune and inflammatory responses.18  As SCD is 
characterized by elevated leukocyte counts,19 circulating endothelial cells20 and a 
hypercoaguable state,21 platelet CD40L may play a similar role in SCD as it does in other 
vascular diseases.22,23  Our findings that the elevation of biologically active soluble CD40L in 
plasma correlates to the SCD clinical state24 further suggest that understanding platelet 
activation and subsequent CD40L release may be essential for understanding and alleviating 
symptoms of SCD. 
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The integrin αIIbβ3 is critical for platelet aggregation, adhesion, granule secretion, and 
platelet-induced procoagulant activity.25,26  Blockade of αIIbβ3 inhibits thrombotic vessel 
occlusion,27 the prothrombin activation that leads to coagulation,28 as well as platelet release 
of inflammatory CD40L.29  The antagonism of αIIbβ3 may therefore be beneficial to SCD 
patients as it may reduce many of the factors contributing to the adhesive, pro-inflammatory, 
and hypercoaguable state of the SCD vasculature.    
 
Eptifibatide, or Integrilin®, is an αIIbβ3 antagonist shown to be safe and effective in treating 
acute coronary syndromes (ACS).30,31  Blockade of αIIbβ3 via eptifibatide also effectively 
decreases the release of platelet CD40L,29 suggesting possible therapeutic benefit to SCD 
patients.  Therefore, we asked if eptifibatide could safely lower CD40L levels when 
administered to patients with SCD.  We also assessed changes in the inflammatory profile of 
eptifibatide-treated SCD patients and determined if comparable pharmacodynamics observed 
in the treatment of ACS could be achieved within the complex hemodynamics of SCD. 
 
 
Materials and Methods 
Study Participants 
Approval for this study was obtained from the Committee on the Protection of the Rights of 
Human Subjects at the University of North Carolina-Chapel Hill with informed consent 
provided according to the Declaration of Helsinki.  Study participants were eligible if they 
met the following criteria: 1) adults (age 18 to 50 years) with a confirmed diagnosis of 
homozygous SCD (Hb SS); 2) had no history of acute vaso-occlusive events requiring 
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hospitalization over the preceding 6 weeks; 3) had clinically acceptable values for 
hematology, chemistry, urinalysis and electrocardiogram for a patient with SCD; 4) had a 
negative pregnancy test, if female; 5) had a clinically acceptable physical examination; 6) 
had no evidence of infiltrates on a chest x-ray; and 7) weighed ≤ 100 kg. Patients were 
excluded from participating in the study if: 1) they were pregnant or breastfeeding; 2) had 
laboratory values that indicated major organ dysfunction (e.g. serum creatinine > 2.0, AST 
and/or ALT > 3 times normal); 3) had received a red blood cell transfusion within the 
previous 3 months; 4) had a history of clinically significant active cardiovascular, neurologic, 
endocrine, hepatic or renal disorder; 5) uncontrolled hypertension; 6) previous hemorrhagic 
stroke; 7) had a history of recent illicit drug or alcohol abuse; 8) had been exposed to any 
investigational drug within the preceding 6 weeks; 9) they were on chronic anticoagulation 
therapy; and 10) they were on aspirin, non-steroidal anti-inflammatory drugs or other anti-
platelet medications.  
 
Patient Characteristics  
Four subjects were enrolled onto this open-label Phase I study. All of the subjects were 
studied in their non-crisis, steady states.  All study subjects were male and had homozygous 
SCD (Hb SS). The median age was 31.5 years (range from 20 to 34 years). Three of the four 
study subjects were on hydroxyurea therapy at the time of evaluation. 
 
Treatment Plan 
The study was an open-label trial to evaluate the safety, and pharmacodynamics of 
eptifibatide in patients with SCD in the steady, non-crisis state. The study was divided into 
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four phases: a screening phase; a treatment phase; a post-treatment phase; and a follow-up 
phase. Eligible study subjects were admitted to the General Clinical Research Center 
(GCRC) one day prior to commencement of study drug administration. On the day of study 
drug administration, two baseline samples (i.e., time –30 min) for platelet aggregation studies 
and plasma CD40L were obtained using a 21-gauge needle.  Beginning immediately 
thereafter, each subject received two 180 µg/kg boluses of Eptifibatide 10 minutes apart, 
followed immediately by a continuous infusion at 2 µg/kg/min for a total of 6 hours.  
Throughout this treatment phase, safety assessments were obtained by monitoring vital signs, 
clinical laboratory test results (complete blood counts, PT/PTT and renal and liver function tests), and 
any observed or reported adverse events.  The post-treatment phase began immediately after the 
eptifibatide infusion was completed and lasted for a total of 24 hours.  Seven days after 
completion of the study-drug infusion, each subject returned as an outpatient for the follow-
up phase, which involved a thorough history and physical examination, a detailed assessment 
for adverse events, clinical laboratory safety tests, and final plasma samples for 
pharmacodynamic analyses. 
 
Platelet aggregation 
The pharmacodynamics of Eptifibatide in this patient population was analyzed by performing 
platelet aggregation studies on platelet rich plasma samples taken prior to the study drug 
infusion, immediately following discontinuation of the drug, and at the 7-day post-infusion 
follow-up.  For all platelet aggregation studies, the blood samples were drawn into 1.2 mM 
PPACK, rested for 15 min at 37ºC, then centrifuged at 200g for 15 minutes before the red 
and white blood cells were removed.  Aggregation was then measured in platelet-rich plasma 
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by an optical aggregometer (Chrono-Log, Havertown, PA) using autologous platelet-poor 
plasma as a reference and either 20µM ADP or 5µM TRAP6 as agonists. 
 
CD40L, beta-thromboglobulin (βTG) and platelet factor 4 (PF4) measurement 
Peripheral blood samples were collected by venipuncture from the antecubital vein via a 21-
gauge needle into 0.13M sodium citrate.  To separate plasma from blood cells, samples were 
centrifuged at 200g, PGI2 (1U/mL) was then added to plasma before removing platelets at a 
750g centrifugation, and microparticles at a 16,000g centrifugation.  Each centrifugation was 
15 minutes in duration and was preceded by a 15-30 minute rest of platelets at 37ºC.  
According to the manufacturer’s recommendations, a fibrin clot was formed by the addition 
of 1U thrombin/mL plasma.  The resulting defibrinated plasma was stored at -80ºC until it 
was analyzed.  CD40 ligand, βTG and PF4 levels were measured in thawed plasma with 
ELISA kits (Alexis Biochemicals, San Diego, CA and American Diagnostica, Greenwich, 
CT, respectively).  Both assays rely on antibody capture techniques and horseradish 
peroxidase conjugates.  Reactions are developed using a tetramethylbenzidine developing 
solution. 
 
Luminex Assays 
Plasma levels of inflammatory cytokines were measured using luminex MAP technology.32  
Briefly, specific fluorescent microspheres were used to recognize target analytes in human 
plasma samples.  Dual lasers identified microspheres and allowed the amount of analyte 
bound to be quantified.  Assays were performed by Rules Based Medicine (Houston, TX).   
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Flow cytometry 
Platelet exposure of P-selectin and CD40L were measured by whole blood flow cytometry as 
described previously.33  Briefly, 5 µl of whole blood obtained from 0.13M sodium citrate 
anti-coagulated blood was incubated with either FITC-conjugated anti-CD62P and PE-
conjugated anti-CD40L or appropriate fluorophore- and isotype- matched control antibodies 
(BD PharMingen, San Diego, CA).  Samples were incubated at room temperature for 30 
minutes, fixed with 0.7% paraformaldehyde, and read by a FACScan flow cytometer (Becton 
Dickinson, San Jose, CA).  Platelets were selected based on characteristic forward- and side-
scatter profiles. 
 
Results  
Safety  
Eptifibatide was well tolerated by the study subjects. The patients did not experience any 
side-effects that were thought to be secondary to the administration of eptifibatide. One 
subject complained of 2 days of a sore throat and a non-productive cough on his day 7 
follow-up visit that was thought to be due to a viral upper respiratory tract infection.  There 
were no bleeding manifestations or clinically meaningful changes in any of the safety 
laboratory studies (hematological, biochemical, or coagulation parameters) that were 
evaluated before, during and following eptifibatide infusion.   
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Platelet granule release and aggregation to leukocytes in SCD plasma is not increased by 
eptifibatide treatment 
Despite the reduction in platelet:platelet aggregation, eptifibatide has been reported to 
increase some markers of platelet activation and the degree of platelet:leukocyte 
aggregation.34  Therefore, platelet activation markers β-thromboglobulin (β-TG) and platelet 
factor 4 (PF4) were measured to determine if eptifibatide increases platelet granule release in 
patients with SCD.  Neither β-TG nor PF4 were increased by eptifibatide treatment (Figure 
12A).  Furthermore, surface expression of platelet P-selection remained unchanged in the 
study subjects as a result of eptifibatide treatment (Figure 12B).  Blood cells simultaneously 
positive for the leukocyte marker CD45 and the platelet marker GPIX were analyzed by 
whole blood flow cytometry to determine the amount of platelet:leukocyte aggregates in 
SCD patient samples.  The high degree of platelet:leukocyte aggregates found in the blood of 
patients with SCD was not increased by treatment with eptifibatide, remaining near constant 
for all time points measured (Figure 12C).  These results suggest that the already high level 
of platelet granule release and aggregation to leukocytes that exists in SCD is not increased 
by treatment with eptifibatide. 
 
Elevated CD40L in SCD plasma is reduced by eptifibatide treatment  
Soluble CD40L levels in cell-free SCD plasma were measured.  Six hours following 
eptifibatide infusion, soluble plasma CD40L levels were decreased in 3 of the 4 patients 
studied.  CD40L levels remained unchanged for 1 patient (Figure 13).  On average, soluble 
CD40L levels were reduced by approximately 35% in those patients whose plasma CD40L 
were decreased following eptifibatide treatment (Figure 13B).  Given that higher levels of 
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soluble CD40L may be predictive of vascular inflammation,35 these results suggest that 
eptifibatide treatment may be beneficial in reducing vascular inflammation and the risk of 
adverse cardiovascular events in patients with SCD.   
 
The profile of inflammatory indicators in SCD plasma is altered by eptifibatide treatment 
Plasma from patients with SCD was assayed for expression of inflammatory indicators 
before and after treatment with eptifibatide.  Myoglobin, an indicator of damage to muscle 
tissue, was reduced by an average of 35%, macrophage inflammatory protein-1 alpha (MIP-
1α) expression was reduced by 37%, and tumor necrosis factor alpha (TNFα) was reduced 
by 32% (Figure 14A).  Conversely, eptifibatide treatment increased matrix 
metalloproteinases MMP-2 and MMP-9 by an average of 34% and 81%, respectively (Figure 
14B).  The adipokine leptin was similarly increased by an average 70% in plasma from SCD 
patients following eptifibatide treatment (Figure 14C).   
 
Eptifibatide inhibits platelet aggregation in SCD patients 
The inhibition of ex vivo platelet aggregation by eptifibatide was examined in patients with 
SCD.  Platelet response to adenosine diphosphate (ADP) and thrombin receptor activating 
peptide (TRAP) was measured in all 4 study subjects at baseline, 6-hours, 24-hours, and 7-
days post eptifibatide infusion.  Eptifibatide significantly inhibited platelet aggregation in all 
4 subjects studied (Figure 15).  We found ADP-induced platelet aggregation to be inhibited 
by approximately 90% immediately following eptifibatide infusion (6-hours post infusion).  
Aggregation induced by varying concentrations of TRAP was inhibited by approximately 46-
67%.  Aggregation returned to normal at the 24-hour time point for all agonists.  
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Discussion 
Sickle cell disease is characterized by increased thrombin generation, abnormal activation of 
fibrinolysis, increased platelet activation and decreased levels of anticoagulant proteins.1   
Additionally, increased levels of soluble tissue factor (TF) combined with TF-expressing 
endothelial cells and microparticles36,37 constitute a hypercoagulable state of multifactorial 
etiology.  The quagmire of vaso-occlusive events is compounded by an abnormal RBC 
membrane phospholipid asymmetry,7,38 the adherence of sickle RBCs to vascular 
endothelium,2 as well as ischemia-reperfusion injury.3  In addition, SCD is an inflammatory 
state, as evidenced by chronic elevation of leukocyte counts, abnormal activation of 
granulocytes and monocytes4,5 and chronically elevated levels of multiple inflammatory 
mediators.2 
 
Platelet hyperactivity and increased release of the inflammatory mediator CD40L 
characterize the vascular pathogenesis of SCD just as it does in other inflammatory vascular 
diseases including ACS.  Antagonism of platelet integrin αIIbβ3 by eptifibatide has proven 
to be safe and effective for the treatment of ACS, with patients benefiting from the inhibition 
of platelet aggregation and CD40L release.  Improved clinical status of ACS patients due to 
Eptifibatide treatment was seen despite in vitro reports of granule release and 
platelet:leukocyte aggregation resulting from occupation of αIIbβ3 by the antagonist.  
Eptifibatide may prove to be beneficial in the treatment of SCD as well.  However, the 
unique hemodynamics of SCD may make these patients less tolerant of residual αIIbβ3 
activation caused by eptifibatide than the normal volunteers and ACS patients studied in 
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previous safety trials.  Here we show that eptifibatide can be safely administered to SCD 
patients, that eptifibatide treatment may promote a favorable alteration of cytokine 
expression in SCD, and that the beneficial effects of decreased platelet aggregation and 
CD40L release are still achieved. 
 
Eptifibatide was well tolerated by SCD patients.  No adverse events were reported during the 
study, and there were no significant changes in any of the hematological, chemical, or 
coagulation parameters measured as a result of Eptifibatide infusion.  Furthermore, SCD 
patients receiving Eptifibatide did not show increased platelet granule release as a result of 
drug treatment (Figure 12).  Although elevated beyond normal levels, platelet activation 
markers β-TG and PF4 were not further increased by Eptifibatide treatment of the SCD 
patients in this study (Figure 12A).  Similarly, platelet exposure of P-selectin remained 
relatively constant following Eptifibatide infusion for all time points studied (Figure 12B).  
Platelet:leukocyte aggregates were also not increased in SCD patients following eptifibatide 
treatment (Figure 12C).  Collectively, these results suggest that antagonism of platelet 
integrin αIIbβ3 by eptifibatide does not increase platelet activation in the context of SCD and 
may be suitable for use in the treatment of SCD.  
 
We also demonstrate in this study that soluble CD40L is reduced by eptifibatide treatment in 
75% of SCD patients tested (Figure 13).  Reductions averaged 35% in these patients (Figure 
13B), suggesting that in addition to its safe administration, eptifibatide treatment may lower 
CD40L levels in SCD patients.  As elevated CD40L is a potential indicator of vascular 
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inflammation39 and may correlate to the SCD clinical state,24 reductions in CD40L levels are 
likely to be beneficial to SCD patients. 
 
Indeed, multiple inflammatory cytokines were reduced following eptifibatide treatment 
(Figure 14).  As MIP-1α and TNFα are potent mediators of inflammation, reduced 
expression of these cytokines might result in beneficial effects for the SCD patient.  
Furthermore, a decrease in the injury indicator myoglobin may be further evidence of a 
therapeutic benefit of eptifibatide treatment for SCD patients.  Upregulation of the matrix 
metalloproteinases MMP-2 and MMP-9 (Figure 14B) is consistent with vessel dilation, as is 
an increase in the adipokine leptin (Figure 14C).   
 
Pharmacodynamic studies of eptifibatide have largely focused on its short-acting, reversible 
decrease in platelet aggregation.  However, benefits to patients receiving eptifibatide are 
significant even a year following treatment.40  One-year hazard ratios demonstrate a 
decreased risk of death and myocardial infarction following eptifibatide treatment,41 
suggesting that a one-time dose of the αIIbβ3 antagonist has long lasting effects.  Since 
eptifibatide inhibition of platelet aggregation in SCD patients was comparable to results 
achieved in ACS treatment (Figure 15), SCD patients could presumably enjoy lasting benefit 
from eptifibatide treatment as well.    
 
This study demonstrates that eptifibatide is safe for use in SCD patients.  Furthermore, these 
data demonstrate that the effective inhibition of αIIbβ3-mediated platelet aggregation in SCD 
is comparable to that shown in ACS.  Additionally, 75% of these patients demonstrated a 
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decrease in CD40L levels.  As eptifibatide infusion led to a favorable alteration in the 
inflammatory profile of the plasma of these SCD patients, eptifibatide may have additional 
benefits for SCD patients.  These results suggest that eptifibatide may be an effective 
treatment modality for the vascular occlusion that occurs in patients with SCD.  Future 
studies designed to establish the efficacy of eptifibatide in SCD are therefore warranted.  
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Figure 12.  Eptifibatide treatment did not increase platelet activation in SCD plasma. 
(A) Platelet activation markers beta-thromboglobulin (β-TG) and platelet factor 4 (PF4) were 
measured by ELISA in cell-free SCD plasma at the indicated time points.  Baseline measurement of 
β-TG in SCD plasma averaged 193.9 IU/ml ± 7.7 IU/ml.  Plasma levels of β-TG were unchanged by 
Eptifibatide treatment.  Similarly, the average PF4 level of 77.8 IU/ml ± 10.9 IU/ml remained the 
same following Eptifibatide treatment.  Results shown were normalized relative to baseline.  (B) 
Surface expression of platelet P-selectin was analyzed by whole blood flow cytometry.  Mean 
fluorescence intensity (MFI) of the P-selectin fluorophore remained relatively unchanged as a result 
of Eptifibatide treatment.  (C) Whole blood from SCD patients was analyzed by flow cytometry.  
Leukocytes and platelets were selected by CD45 and GPIX specificity, respectively.  Co-incidence of 
the leukocyte and platelet markers indicate that the amount of platelet:leukocyte aggregates in SCD 
patient samples was not increased by Eptifibatide treatment.   
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Figure 13.  Elevated CD40L in SCD plasma is reduced by eptifibatide treatment 
CD40L levels were measured in cell-free SCD plasma collected at time points indicated.  For SCD 
patients 1, 2 and 4, ELISA results demonstrate a reduction in soluble CD40L at the 6h time point.  
Levels of plasma CD40L returned to baseline by the 24h time point.  Soluble CD40L remained 
unchanged for SCD patient 3.  (B) Eptifibatide treatment reduced CD40L levels by an average 35% 
for SCD patients 1, 2 and 4 as shown for the 6h time point.  Results shown represent mean ± SEM. 
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Figure 14 
 
 
Figure 14.  The profile of inflammatory indicators in SCD plasma is altered by 
eptifibatide treatment.  (A) Average plasma concentration of myoglobin dropped from 6.9 
ng/ml to 4.1 ng/ml, MIP-1α dropped from an average 12.3 pg/ml to 8.6 pg/ml, and average 
TNFα concentration was reduced from 7.0 pg/ml to 4.6 pg/ml.  Reductions in myoglobin, 
MIP-1α and TNFα following eptifibatide infusion averaged 35%, 37% and 32%, 
respectively, for each patient. (B) Matrix metalloproteinases MMP-2 (334 ng/ml to 
434 ng/ml) and MMP-9 (448 ng/ml to 596 ng/ml) increased average concentrations 34% and 
81%, respectively, in SCD patient plasma following eptifibatide infusion.  (C) Leptin 
concentrations increased from 0.78 ng/ml to 1.04 ng/ml following eptifibatide infusion, an 
average 1.84-fold increase in expression.  Data shown determined by Luminex multiplex 
analysis of EDTA-anticoagulated patient plasma. 
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Figure 15.  Eptifibatide inhibits platelet aggregation in SCD  patients 
The extent of ex vivo platelet aggregation inhibition with eptifibatide was examined in patients with 
SCD disease.  Platelet response to ADP and TRAP was measured in four steady state, homozygous 
SCD patients at baseline, 6-hours, 24-hours, and 7-days post eptifibatide infusion.  (A) Eptifibatide 
inhibited platelet aggregation to 20 µM ADP by approximately 90%, **p<0.001.  (B-D)  Platelet 
aggregation was inhibited ~67% in response to 12.5 µM TRAP*, ~54% in response to 25 µM 
TRAP*, and ~46% in response to 50 µM TRAP, *p<0.05.  Aggregation profiles returned to baseline 
levels within 24 hours and were unchanged 7 days post eptifibatide infusion.  
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CHAPTER V. 
CONCLUSIONS 
 
CD40L mediates chronic inflammation in multiple disease states1.  B cell proliferation,2 
endothelial adhesion molecule expression,3 and procoagulant activity through tissue factor 
upregulation4 are all mechanisms by which CD40L exerts its inflammatory effects.  All of 
these indices of inflammation characterize SCD,5 but by unknown mechanisms.  SCD is also 
characterized by increased platelet activity, suggesting that the vast amount of CD40L stored 
in platelets6 are prone to surface exposure and release as soluble fragments into the 
bloodstream.7 Therefore, CD40L might be more available and mediating the chronic 
inflammation that occurs in SCD patients.  Prior to this work, the role of platelets and the 
inflammatory protein CD40L in SCD pathology had not been clearly established.  Here we 
present evidence that platelets participate in the chronic inflammation of SCD via CD40L 
and provide new insights into mechanisms contributing to SCD pathology. 
 
Just as sCD40L levels are elevated in a variety of diseases involving vascular 
inflammation,8-10 we found that sCD40L is elevated in SCD as well.  Indeed, our findings 
indicate an average 30-fold elevation of sCD40L in SCD versus normal plasma.  We also 
demonstrate a corresponding decrease in the amount of CD40L stored in the platelets of SCD 
patients, more than enough to account for the increased plasma amounts measured.  The 
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elevated sCD40L in SCD plasma positively correlates with increased TF and participates in 
the induction of TF, VCAM-1 and ICAM-1 expression via its interaction with CD40.  
Biological activity of sCD40L in SCD plasma is further confirmed by its induction of B cell 
proliferation.  Together, these data identify sCD40L as potentially important for both 
inflammation and coagulation in SCD, and suggest a previously unrealized participation of 
platelets in SCD pathogenesis. 
 
In vivo studies of the organ pathology in SCD provide further evidence of the role the potent 
inflammatory mediator CD40L plays in this disease.  Following bone marrow transplantation 
to convey the SCD phenotype to mice, the effects of anti-CD40L treatment or the lack of 
endothelial CD40 or β3 integrin were examined.  In the SCD mice where CD40L activity 
was inhibited, there was significantly less lung, liver and kidney damage as shown by 
immunohistochemical staining for iron and fibrin deposits.  Even more impressively, the 
spleens of anti-CD40L treated mice appeared normal compared to the disrupted architecture 
and grossly enlarged spleens typical of SCD.  Furthermore, the lack of CD40 was protective 
against the accumulation of lung pathology in the BMT SCD mice.  These results 
demonstrate a role for CD40L in the development of organ damage in SCD, and suggest that 
blocking CD40L activity could reduce the damage that accumulates in the vital organs of 
SCD patients. 
 
Platelet hyperactivity and increased release of the inflammatory mediator CD40L 
characterize the vascular pathogenesis of SCD just as it does in other inflammatory vascular 
diseases including ACS.  Antagonism of platelet integrin αIIbβ3 by eptifibatide has proven 
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to be safe and effective for the treatment of ACS, with patients benefiting from the inhibition 
of platelet aggregation and CD40L release.  Improved clinical status of ACS patients due to 
eptifibatide treatment was seen despite in vitro reports of granule release and 
platelet:leukocyte aggregation resulting from occupation of αIIbβ3 by the antagonist.  
Eptifibatide may prove to be beneficial in the treatment of SCD as well.  However, if 
eptifibatide occupancy of αIIbβ3 causes residual outside-in platelet activation, the unique 
hemodynamics of SCD may make these patients less tolerant of residual platelet activity than 
the normal volunteers and ACS patients studied in previous safety trials.  Here we show that 
eptifibatide can be safely administered to SCD patients. Furthermore, these data demonstrate 
that the effective inhibition of αIIbβ3-mediated platelet aggregation in SCD is comparable to 
that shown in ACS.  Additionally, 75% of these patients demonstrated a decrease in CD40L 
levels.  As eptifibatide infusion led to a favorable alteration in the inflammatory profile of the 
plasma of these SCD patients, eptifibatide may have additional benefits for SCD patients.  
These results suggest that eptifibatide may be an effective treatment modality for the vascular 
occlusion that occurs in patients with SCD.  The extent to which eptifibatide, or other platelet 
antagonist, may be effective as a treatment modality for SCD should be determined.  
 
Together, these data provide new insights into mechanisms of inflammation in SCD.  The 
findings presented here suggest that platelet CD40L plays an important role in the 
inflammatory processes of SCD and in the resulting pathology.  Furthermore, these results 
suggest a mechanistic link by which the mutated hemoglobin of sickle RBC leads to the 
numerous downstream effects of inflammation, vascular occlusion and hypercoagulation.  
The process of sickling damages the RBC of SCD such that membrane leakiness releases 
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ADP11-13 and phospholipid asymmetry exposes phosphatidylserine.14  Therefore, sickle RBC 
can be irritants,15 provoking a variety of effects that include platelet activation.11 Activated 
platelets expose CD40L to their surface16 and release soluble CD40L fragments.7   
 
When CD40L is no longer encrypted in platelets, the multifunctional inflammatory mediator 
can cause a host of proinflammatory and procoagulant effects.3  B cell proliferate,17 VCAM-
1 and ICAM-1 expression is upregulated,18 and tissue factor production is increased;19,20 all 
in response to CD40 ligation.  Increased leukocyte counts, endothelial activation, and 
procoagulant activity are SCD characteristics associated with increased vascular occlusion21 
and more clinically severe SCD,22,23 with an increased propensity for the sickling of slowly 
transversing RBC.   
 
A model for chronic inflammation in SCD is proposed here (Figure 16) where we present 
graphically how this self-perpetuating process predisposes SCD patients to recurring and 
ongoing inflammation.  As presented here, this repetitive cycle requires both platelet 
activation and CD40L activity.  Therefore, platelets and CD40L are identified as two 
potential therapeutic targets to interrupt the chronic inflammatory cascade and treat the 
manifestations of SCD. 
 
This research goes on to suggest that a particular platelet antagonist, eptifibatide, may be 
beneficial to SCD patients.  Pending more extensive studies, interventional therapy with the 
αIIbβ3 antagonist could provide lasting benefits for SCD patients just as it does for patients 
with ACS.24  If this or other mechanisms aimed at antagonizing platelet activation and 
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reducing CD40L activity are employed in SCD, these patients could potentially enjoy longer 
life spans, less pain crises, fewer hospitalizations, and overall better health as a result.   
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Figure 16. Potential model of platelet CD40L role in chronic inflammation in SCD.  
Hemoglobin S abnormally polymerizes upon deoxygenation, causing distorted, sickle-shaped 
RBC. Repetitive sickling damages RBC membranes, causing phosphatidylserine exposure 
and the release of ADP. Platelets in turn become activated, exposing and releasing CD40L.  
CD40L mediates B cell proliferation, endothelial activation, and TF production. These 
processes increase the propensity for vascular occlusion. RBC transit through the vasculature 
is slowed, oxygenation is delayed, sickling is increased and a persistent cycle of chronic 
inflammation ensues.   
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